Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Indication of EGFR kinase inhibitors should be refined].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2011

Heneberg P

Abstract excerpt

Even though lung cancer incidence began to decline in the majority of industrialized countries, is still belong to cancers with one of the highest incidence and mortality rates. In the Czech Republic, epidermal growth factor receptor (EGFR) kinase activity inhibitors erlotinib and gefitinib are approved for the use as the second- and third-line treatment of non-small-cell lung cancer. In a cohort of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 21644362

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Indication of EGFR kinase inhibitors should be refined].PMID 21644362Read ↗

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].Semantic proximity Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Semantic proximity Read ↗

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity Read ↗

[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].Semantic proximity Read ↗

Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.Semantic proximity Read ↗

[Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers].Semantic proximity Read ↗

[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)].Semantic proximity Read ↗

[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.